Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
5m
Hosted on MSNHims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
1d
Medpage Today on MSNSemaglutide Tied to Small Risk of Potentially Blinding Eye ConditionThe use of semaglutide (Ozempic) was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in ...
WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
ABC News on MSN8d
Weight loss drug semaglutide may reduce alcohol cravings, heavy drinking and smoking, new study findsSemaglutide, a medication widely used for diabetes and weight loss, may offer another unexpected benefit -- it could help ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
Adults with type 2 diabetes may have a higher risk for developing nonarteritic anterior ischemic optic neuropathy while using ...
A recent review and meta-analysis of semaglutide studies found that this drug can significantly reduce the risk of hospitalization from heart failure and deaths from cardiovascular causes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results